Weight changes with depot neuroleptic maintenance therapy.
A prospective study of schizophrenic patients prescribed injectable depot neuroleptic drugs as maintenance therapy showed a clinically significant weight gain in 55% of patients. No significant difference was shown between flupenthixol decanoate and fluphenazine decanoate, nor was a clinically meaningful relationship shown with dose, or the use of anti-parkinsonian drugs. The weight gain continued for at least 2 years following a mental state relapse. It is suggested that the monitoring of weight and giving of appropriate advice on diet are two essential in maintenance therapy of chronic schizophrenia.
D001835:Body Weight / Q000187:drug effects*; D003651:Decanoates; D003692:Delayed-Action Preparations; D005475:Flupenthixol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D011446:Prospective Studies; D012559:Schizophrenia / Q000188:drug therapy*; D013997:Time Factors
D003651:Decanoates; D003692:Delayed-Action Preparations; D005475:Flupenthixol; D005476:Fluphenazine